Amarin Reports Fourth Quarter and Year-End 2013 Financial Results and Provides Update on Operations
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
Aegis Capital Keeps Amarin (AMRN) at 'Hold'; Cautious on Vascepa for Dyslipidemia Strategy
February 28, 2014 9:22 AM ESTAegis Capital reaffirms its Hold rating and $2 price target on Amarin Coop plc (Nasdaq: AMRN) on Friday following Q4 results and update.
Analyst Ram Selvaraju commented, We believe that Amarin can achieve management's stated financial goals, even with a significantly reduced revenue base for Vascepa in hypertriglyceridemia only. However, we remain... More
Amarin Corp Plc (AMRN) Posts Q4 Loss of 26c/Share; Update on Ops
February 27, 2014 4:03 PM ESTAmarin Corp Plc (NASDAQ: AMRN) reported Q4 EPS of ($0.26), $0.03 worse than the analyst estimate of ($0.23). Revenue for the quarter came in at $10.1 million versus the consensus estimate of $11.17 million.
Key Amarin milestones since September 30, 2013 include:
-- Recognized $26.4 million in product revenue from Vascepa® sales in 2013, the first year of Vascepa sales, including revenue growth to... More
